Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy.
about
Cardiotoxicity in childhood cancer survivors: strategies for prevention and managementDecoding Warburg's hypothesis: tumor-related mutations in the mitochondrial respiratory chainAn experimental approach to study the function of mitochondria in cardiomyopathyTime-dependent and somatically acquired mitochondrial DNA mutagenesis and respiratory chain dysfunction in a scleroderma model of lung fibrosisPotential biomarkers in mouse myocardium of doxorubicin-induced cardiomyopathy: a metabonomic method and its applicationA Biophysical Systems Approach to Identifying the Pathways of Acute and Chronic Doxorubicin Mitochondrial CardiotoxicityCyclophosphamide leads to persistent deficits in physical performance and in vivo mitochondria function in a mouse model of chemotherapy late effects.Ozone-Oxidative Preconditioning Prevents Doxorubicin-induced Cardiotoxicity in Sprague-Dawley RatsP53 inhibition exacerbates late-stage anthracycline cardiotoxicity.Mitochondrial topoisomerase I (top1mt) is a novel limiting factor of doxorubicin cardiotoxicity.Anthracycline cardiotoxicity: from bench to bedside.Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies.Cardiovascular effects in childhood cancer survivors treated with anthracyclines.Differences in doxorubicin-induced apoptotic signaling in adult and immature cardiomyocytes.Oral glutamine protects against acute doxorubicin-induced cardiotoxicity of tumor-bearing rats.Anthracycline-containing chemotherapy causes long-term impairment of mitochondrial respiration and increased reactive oxygen species release in skeletal muscle.Anthracycline treatment and ventricular remodeling in left ventricular assist device patients.MicroRNA-532-3p regulates mitochondrial fission through targeting apoptosis repressor with caspase recruitment domain in doxorubicin cardiotoxicity.Cardiac overexpression of 8-oxoguanine DNA glycosylase 1 protects mitochondrial DNA and reduces cardiac fibrosis following transaortic constrictionAnalysis of proteome changes in doxorubicin-treated adult rat cardiomyocyte.Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in ratsEffects of moderate global maternal nutrient reduction on fetal baboon renal mitochondrial gene expression at 0.9 gestationEffects of fermented Cordyceps sinensis on oxidative stress in doxorubicin treated rats.Analysis of redox and apoptotic effects of anthracyclines to delineate a cardioprotective strategy.The differential effects of green tea on dose-dependent doxorubicin toxicity.Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.Iron chelators with topoisomerase-inhibitory activity and their anticancer applications.Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors.After the chemotherapy: potential mechanisms for chemotherapy-induced delayed skeletal muscle dysfunction in survivors of acute lymphoblastic leukaemia in childhood.Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management.Sirt3 protects mitochondrial DNA damage and blocks the development of doxorubicin-induced cardiomyopathy in mice.Doxorubicin inactivates myocardial cytochrome c oxidase in rats: cardioprotection by Mito-QSystemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes.CaMKII in the cardiovascular system: sensing redox states.Biological drugs: classic adverse effects and new clinical evidences.An expert opinion on pharmacologic approaches to reducing the cardiotoxicity of childhood acute lymphoblastic leukemia therapies.Mitochondria as key targets of cardioprotection in cardiac ischemic disease: role of thyroid hormone triiodothyronine.Current views on anthracycline cardiotoxicity.Chemotherapy-induced cardiotoxicity in children.The role of TNF-α, Fas/Fas ligand system and NT-proBNP in the early detection of asymptomatic left ventricular dysfunction in cancer patients treated with anthracyclines
P2860
Q24628695-59A977F4-0601-4A31-A60F-DE2CFF4FCFA3Q26783724-F62393BB-A934-4050-9BEE-836AF4E54ED7Q26801342-528A8322-804D-4AF7-A023-1C7DAF27B833Q28388130-91E1E0C5-F82C-4AEE-B6A6-EA4CC548CAEBQ28478019-55DD2517-5584-4B76-B54A-F5D0760E99C6Q28553631-03597106-D956-42C1-823D-FC2B9E9BD986Q33897890-6B03E06E-CEC1-4125-95E9-BE74F09579E9Q33982934-8FD57764-5BA1-4B08-B29A-8B634BAD331CQ34048273-94D77CC1-6A1B-4E3C-B8A6-77CB5E1D188FQ34203187-E58D52F4-A589-4C17-B5D6-8DEC148488B4Q34477415-6B3EB40E-6FCD-412C-A56E-84C2EDA65A66Q34563378-6F962DF6-D3E1-417D-B57A-4CA38A52BFFAQ34572109-11EB152E-6805-4AF4-A2CF-91B27C4A6B04Q34576324-3F57BCB6-A42D-4E67-ABA0-6A24AE003B00Q35011294-5CBCA6A7-35C3-42F8-9626-F7CFAE72C57DQ35138773-765D759F-2AC5-4742-9C3D-9376B4080A31Q35246219-82247669-84E1-4FDC-B265-70B2CFE80AD5Q35274471-6A55331A-D159-4C62-B16A-091D416D73AAQ35543526-41F73681-5BE2-4C0D-AB78-F98634128585Q35816653-6DFCAE35-E15A-45B3-8505-CF7C92FB1CBEQ36053116-A5A2D658-7405-4925-AF53-DD89998B3655Q36104528-E1F33BBF-B2D6-4AC1-80D5-81D50AFFB74EQ36209961-6019999F-3C73-4C6C-BBC9-850C30A9A5B1Q36296724-877F95F8-467E-4396-94E4-3FF615072792Q36398643-5DAD5165-4B77-411F-8753-2777E4F23D3DQ36568908-80C148F9-87D0-4EC9-A386-0800298DCA6DQ36568915-7A835DFE-B0FB-4D34-8BC2-DEDB79355DE8Q36649653-3C664653-D4DF-42D1-8E15-CA7C5B250E51Q36778333-1233BE06-C096-408A-A54B-156B08D8F264Q36828128-00C65CE4-FC0D-437F-8F65-67D0E9FB0EF2Q36902292-002AFE2E-9B57-4336-993A-B98E760BDE64Q37279228-C9B02632-AE87-452D-892D-B333B997CEAFQ37282125-C68BB1E8-2331-406D-B748-433CE2D18400Q37899670-552322B2-29BA-4194-AF30-9FA147D99D8DQ38015746-83028C2E-CEAD-432F-B1BD-4A9DC2767798Q38109236-EBFDEB2A-8B2B-4403-8593-AD69018BB2E5Q38391278-3C11F414-F5E2-4835-8BA2-2F482ECA2866Q38845535-13C6E392-508B-44BD-90C2-2CE647638860Q39415815-1256F82C-C513-4A73-BE39-8587DC550936Q40964541-AF7D9A08-1A39-4A03-9D03-3C71E8F859C8
P2860
Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy.
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
Time-dependent and tissue-spec ...... ic doxorubicin cardiomyopathy.
@ast
Time-dependent and tissue-spec ...... ic doxorubicin cardiomyopathy.
@en
Time-dependent and tissue-spec ...... ic doxorubicin cardiomyopathy.
@nl
type
label
Time-dependent and tissue-spec ...... ic doxorubicin cardiomyopathy.
@ast
Time-dependent and tissue-spec ...... ic doxorubicin cardiomyopathy.
@en
Time-dependent and tissue-spec ...... ic doxorubicin cardiomyopathy.
@nl
prefLabel
Time-dependent and tissue-spec ...... ic doxorubicin cardiomyopathy.
@ast
Time-dependent and tissue-spec ...... ic doxorubicin cardiomyopathy.
@en
Time-dependent and tissue-spec ...... ic doxorubicin cardiomyopathy.
@nl
P2093
P1433
P1476
Time-dependent and tissue-spec ...... ic doxorubicin cardiomyopathy.
@en
P2093
Bernhard Setzer
Dirk Lebrecht
Jörg Haberstroh
Ulrich A Walker
Uwe-Peter Ketelsen
P304
P356
10.1161/01.CIR.0000093196.59829.DF
P407
P577
2003-10-20T00:00:00Z